{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T16:06:07Z","timestamp":1779897967384,"version":"3.53.1"},"reference-count":40,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T00:00:00Z","timestamp":1602115200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["DARU J Pharm Sci"],"published-print":{"date-parts":[[2020,12]]},"DOI":"10.1007\/s40199-020-00373-6","type":"journal-article","created":{"date-parts":[[2020,10,8]],"date-time":"2020-10-08T10:03:06Z","timestamp":1602151386000},"page":"661-672","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Design, synthesis, molecular docking study, and antibacterial evaluation of some new fluoroquinolone analogues bearing a quinazolinone moiety"],"prefix":"10.1007","volume":"28","author":[{"given":"Maryam","family":"Norouzbahari","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somayeh","family":"Salarinejad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00fcmtaz","family":"G\u00fcran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gizem","family":"\u015eanl\u0131t\u00fcrk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zahra","family":"Emamgholipour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hamid Reza","family":"Bijanzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahsa","family":"Toolabi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2416-5611","authenticated-orcid":false,"given":"Alireza","family":"Foroumadi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,10,8]]},"reference":[{"key":"373_CR1","doi-asserted-by":"publisher","first-page":"1645","DOI":"10.2147\/IDR.S173867","volume":"11","author":"B Aslam","year":"2018","unstructured":"Aslam B, Wang W, Arshad MI, Khurshid M, Muzammil S, Rasool MH, et al. Antibiotic resistance: a rundown of a global crisis. Infect Drug Resist. 2018;11:1645\u201358.","journal-title":"Infect Drug Resist"},{"key":"373_CR2","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1373\/clinchem.2011.181636","volume":"58","author":"AJ McAdam","year":"2012","unstructured":"McAdam AJ, Hooper DC, DeMaria A, Limbago BM, O'Brien TF, McCaughey B. Antibiotic resistance: how serious is the problem, and what can be done? Clin Chem. 2012;58:1182\u20136.","journal-title":"Clin Chem"},{"key":"373_CR3","doi-asserted-by":"publisher","first-page":"36","DOI":"10.4103\/jgid.jgid_110_18","volume":"11","author":"A Chokshi","year":"2019","unstructured":"Chokshi A, Sifri Z, Cennimo D, Horng H. Global contributors to antibiotic resistance. J Global Infect Dis. 2019;11:36.","journal-title":"J Global Infect Dis"},{"key":"373_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1057\/s41599-019-0263-4","volume":"5","author":"CI Chandler","year":"2019","unstructured":"Chandler CI. Current accounts of antimicrobial resistance: stabilisation, individualisation and antibiotics as infrastructure. Palgrave Commun. 2019;5:1\u201313.","journal-title":"Palgrave Commun"},{"key":"373_CR5","unstructured":"Chao Y-., Farrah K. Fluoroquinolones for the treatment of urinary tract infection: a review of clinical effectiveness, cost-effectiveness, and guidelines. 2019."},{"key":"373_CR6","doi-asserted-by":"publisher","first-page":"167","DOI":"10.3109\/08941939.2013.808461","volume":"26","author":"L Zaffiri","year":"2013","unstructured":"Zaffiri L, Gardner J, Toledo-Pereyra LH. History of antibiotics: from fluoroquinolones to daptomycin (part 2). J Investig Surg. 2013;26:167\u201379.","journal-title":"J Investig Surg"},{"key":"373_CR7","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.ejmech.2018.08.095","volume":"157","author":"F Gao","year":"2018","unstructured":"Gao F, Wang P, Yang H, Miao Q, Ma L, Lu G. Recent developments of quinolone-based derivatives and their activities against Escherichia coli. Eur J Med Chem. 2018;157:1223\u201348.","journal-title":"Eur J Med Chem"},{"key":"373_CR8","doi-asserted-by":"publisher","first-page":"1719","DOI":"10.1039\/C9MD00120D","volume":"10","author":"TD Pham","year":"2019","unstructured":"Pham TD, Ziora ZM, Blaskovich MA. Quinolone antibiotics. Medchemcomm. 2019;10:1719\u201339.","journal-title":"Medchemcomm"},{"key":"373_CR9","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1021\/bi5000564","volume":"53","author":"KJ Aldred","year":"2014","unstructured":"Aldred KJ, Kerns RJ, Osheroff N. Mechanism of quinolone action and resistance. Biochemistry. 2014;53:1565\u201374.","journal-title":"Biochemistry."},{"key":"373_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1093\/jac\/dkg212","volume":"51","author":"MI Andersson","year":"2003","unstructured":"Andersson MI, MacGowan AP. Development of the quinolones. J Antimicrob Chemother. 2003;51:1\u201311.","journal-title":"J Antimicrob Chemother"},{"key":"373_CR11","doi-asserted-by":"publisher","first-page":"268","DOI":"10.3390\/molecules21040268","volume":"21","author":"A Naeem","year":"2016","unstructured":"Naeem A, Badshah SL, Muska M, Ahmad N, Khan K. The current case of quinolones: synthetic approaches and antibacterial activity. Molecules. 2016;21:268.","journal-title":"Molecules."},{"key":"373_CR12","doi-asserted-by":"publisher","first-page":"981","DOI":"10.2174\/156802609789630947","volume":"9","author":"K Drlica","year":"2009","unstructured":"Drlica K, Hiasa H, Kerns R, Malik M, Mustaev A, Zhao X. Quinolones: action and resistance updated. Curr Top Med Chem. 2009;9:981\u201398.","journal-title":"Curr Top Med Chem"},{"key":"373_CR13","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2174\/1381612013398013","volume":"7","author":"VE Anderson","year":"2001","unstructured":"Anderson VE, Osheroff N. Type II topoisomerases as targets for quinolone antibacterials turning Dr. Jekyll into Mr. Hyde. Curr Pharm Des. 2001;7:337\u201353.","journal-title":"Curr Pharm Des"},{"key":"373_CR14","doi-asserted-by":"publisher","first-page":"1152","DOI":"10.1038\/nsmb.1892","volume":"17","author":"A Wohlkonig","year":"2010","unstructured":"Wohlkonig A, Chan PF, Fosberry AP, Homes P, Huang J, Kranz M, et al. Structural basis of quinolone inhibition of type IIA topoisomerases and target-mediated resistance. Nat Struct Mol Biol. 2010;17:1152\u20133.","journal-title":"Nat Struct Mol Biol"},{"key":"373_CR15","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1021\/cr030101q","volume":"105","author":"LA Mitscher","year":"2005","unstructured":"Mitscher LA. Bacterial topoisomerase inhibitors: quinolone and pyridone antibacterial agents. Chem Rev. 2005;105:559\u201392.","journal-title":"Chem Rev"},{"key":"373_CR16","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1016\/S0924-8579(99)00119-3","volume":"13","author":"B Segatore","year":"2000","unstructured":"Segatore B, Setacci D, Perilli M, Franceschini N, Marchetti F, Amicosante G. Bactericidal activity of levofloxacin and ciprofloxacin on clinical isolates of different phenotypes of Pseudomonas aeruginosa. Int J Antimicrob Agents. 2000;13:223\u20136.","journal-title":"Int J Antimicrob Agents"},{"key":"373_CR17","doi-asserted-by":"publisher","first-page":"5774","DOI":"10.1016\/j.bmc.2005.05.063","volume":"13","author":"D Sriram","year":"2005","unstructured":"Sriram D, Yogeeswari P, Basha JS, Radha DR, Nagaraja V. Synthesis and antimycobacterial evaluation of various 7-substituted ciprofloxacin derivatives. Bioorg Med Chem. 2005;13:5774\u20138.","journal-title":"Bioorg Med Chem"},{"key":"373_CR18","doi-asserted-by":"publisher","first-page":"370","DOI":"10.1021\/bi2013905","volume":"51","author":"KJ Aldred","year":"2012","unstructured":"Aldred KJ, McPherson SA, Wang P, Kerns RJ, Graves DE, Turnbough CL Jr, et al. Drug interactions with bacillus anthracis topoisomerase IV: biochemical basis for quinolone action and resistance. Biochemistry. 2012;51:370\u201381.","journal-title":"Biochemistry"},{"key":"373_CR19","doi-asserted-by":"publisher","first-page":"4628","DOI":"10.1093\/nar\/gkt124","volume":"41","author":"KJ Aldred","year":"2013","unstructured":"Aldred KJ, McPherson SA, Turnbough CL Jr, Kerns RJ, Osheroff N. Topoisomerase IV-quinolone interactions are mediated through a water-metal ion bridge: mechanistic basis of quinolone resistance. Nucleic Acids Res. 2013;41:4628\u201339.","journal-title":"Nucleic Acids Res"},{"key":"373_CR20","doi-asserted-by":"publisher","first-page":"2726","DOI":"10.1021\/bi992302n","volume":"39","author":"VE Anderson","year":"2000","unstructured":"Anderson VE, Zaniewski RP, Kaczmarek FS, Gootz TD, Osheroff N. Action of quinolones against Staphylococcus aureus topoisomerase IV: basis for DNA cleavage enhancement. Biochemistry. 2000;39:2726\u201332.","journal-title":"Biochemistry."},{"key":"373_CR21","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.1128\/AAC.45.7.1994-2000.2001","volume":"45","author":"FM Barnard","year":"2001","unstructured":"Barnard FM, Maxwell A. Interaction between DNA gyrase and quinolones: effects of alanine mutations at GyrA subunit residues Ser83and Asp87. Antimicrob Agents Chemother. 2001;45:1994\u20132000.","journal-title":"Antimicrob Agents Chemother"},{"key":"373_CR22","doi-asserted-by":"publisher","first-page":"S180","DOI":"10.1086\/321846","volume":"33","author":"LR Peterson","year":"2001","unstructured":"Peterson LR. Quinolone molecular structure-activity relationships: what we have learned about improving antimicrobial activity. Clin Infect Dis. 2001;33:S180\u20136.","journal-title":"Clin Infect Dis"},{"key":"373_CR23","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s40199-018-0226-0","volume":"26","author":"A Asadipour","year":"2018","unstructured":"Asadipour A, Moshafi MH, Khosravani L, Moghimi S, Amou E, Firoozpour L, et al. N-substituted piperazinyl sarafloxacin derivatives: synthesis and in vitro antibacterial evaluation. DARU J Pharm Sci. 2018;26:199\u2013207.","journal-title":"DARU J Pharm Sci"},{"key":"373_CR24","doi-asserted-by":"publisher","first-page":"4536","DOI":"10.1016\/j.bmcl.2005.07.005","volume":"15","author":"A Foroumadi","year":"2005","unstructured":"Foroumadi A, Emami S, Mehni M, Moshafi MH, Shafiee A. Synthesis and antibacterial activity of N-[2-(5-bromothiophen-2-yl)-2-oxoethyl] and N-[(2-5-bromothiophen-2-yl)-2-oximinoethyl] derivatives of piperazinyl quinolones. Bioorg Med Chem Lett. 2005;15:4536\u20139.","journal-title":"Bioorg Med Chem Lett"},{"key":"373_CR25","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.ejmech.2019.03.018","volume":"170","author":"S Gatadi","year":"2019","unstructured":"Gatadi S, Lakshmi TV, Nanduri S. 4 (3H)-Quinazolinone derivatives: promising antibacterial drug leads. Eur J Med Chem. 2019;170:157\u201372.","journal-title":"Eur J Med Chem"},{"key":"373_CR26","doi-asserted-by":"publisher","first-page":"1915","DOI":"10.1016\/j.bmcl.2005.01.083","volume":"15","author":"S-L Cao","year":"2005","unstructured":"Cao S-L, Feng Y-P, Jiang Y-Y, Liu S-Y, Ding G-Y, Li R-T. Synthesis and in vitro antitumor activity of 4 (3H)-quinazolinone derivatives with dithiocarbamate side chains. Bioorg Med Chem Lett. 2005;15:1915\u20137.","journal-title":"Bioorg Med Chem Lett"},{"key":"373_CR27","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1016\/j.ejmech.2008.10.031","volume":"44","author":"RS Giri","year":"2009","unstructured":"Giri RS, Thaker HM, Giordano T, Williams J, Rogers D, Sudersanam V, et al. Design, synthesis and characterization of novel 2-(2, 4-disubstituted-thiazole-5-yl)-3-aryl-3H-quinazoline-4-one derivatives as inhibitors of NF-\u03baB and AP-1 mediated transcription activation and as potential anti-inflammatory agents. Eur J Med Chem. 2009;44:2184\u20139.","journal-title":"Eur J Med Chem"},{"key":"373_CR28","doi-asserted-by":"publisher","first-page":"1945","DOI":"10.1016\/j.ejmech.2007.12.003","volume":"43","author":"V Jatav","year":"2008","unstructured":"Jatav V, Mishra P, Kashaw S, Stables J. CNS depressant and anticonvulsant activities of some novel 3-[5-substituted 1, 3, 4-thiadiazole-2-yl]-2-styryl quinazoline-4 (3H)-ones. Eur J Med Chem. 2008;43:1945\u201354.","journal-title":"Eur J Med Chem"},{"key":"373_CR29","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1016\/S0960-894X(01)00190-1","volume":"11","author":"Y Xia","year":"2001","unstructured":"Xia Y, Yang Z-Y, Hour M-J, Kuo S-C, Xia P, Bastow KF, et al. Antitumor agents. Part 204: synthesis and biological evaluation of substituted 2-aryl quinazolinones. Bioorg Med Chem Lett. 2001;11:1193\u20136.","journal-title":"Bioorg Med Chem Lett"},{"key":"373_CR30","doi-asserted-by":"publisher","first-page":"476","DOI":"10.4103\/0250-474X.34571","volume":"69","author":"E Jessy","year":"2007","unstructured":"Jessy E, Sambanthan AT, Alex J, Sridevi C, Srinivasan K. Synthesis and biological evaluation of some novel quinazolones. Indian J Pharm Sci. 2007;69:476.","journal-title":"Indian J Pharm Sci"},{"key":"373_CR31","doi-asserted-by":"publisher","first-page":"108","DOI":"10.4103\/0250-474X.22980","volume":"68","author":"V Alagarsamy","year":"2006","unstructured":"Alagarsamy V, Thangathiruppathy A, Rajasekaran S, Vijaykumar S, Revathi R, Anburaj J, et al. Pharmacological evaluation of 2-substituted (1, 3, 4) thiadiazolo quinazolines. Indian J Pharm Sci. 2006;68:108.","journal-title":"Indian J Pharm Sci"},{"key":"373_CR32","doi-asserted-by":"publisher","first-page":"942","DOI":"10.1002\/jhet.3844","volume":"57","author":"MM Reddy","year":"2020","unstructured":"Reddy MM, Sivaramakrishna A. Remarkably flexible quinazolinones\u2014synthesis and biological applications. J Heterocyclic Chem. 2020;57:942\u201354.","journal-title":"J Heterocyclic Chem"},{"key":"373_CR33","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1016\/S0960-894X(03)00376-7","volume":"13","author":"RJ Kerns","year":"2003","unstructured":"Kerns RJ, Rybak MJ, Kaatz GW, Vaka F, Cha R, Grucz RG, et al. Structural features of piperazinyl-linked ciprofloxacin dimers required for activity against drug-resistant strains of Staphylococcus aureus. Bioorg Med Chem Lett. 2003;13:2109\u201312.","journal-title":"Bioorg Med Chem Lett"},{"key":"373_CR34","doi-asserted-by":"publisher","first-page":"5971","DOI":"10.1016\/j.bmcl.2012.07.040","volume":"22","author":"S Wang","year":"2012","unstructured":"Wang S, Jia X-D, Liu M-L, Lu Y, Guo H-Y. Synthesis, antimycobacterial and antibacterial activity of ciprofloxacin derivatives containing a N-substituted benzyl moiety. Bioorg Med Chem Lett. 2012;22:5971\u20135.","journal-title":"Bioorg Med Chem Lett"},{"key":"373_CR35","doi-asserted-by":"publisher","first-page":"1849","DOI":"10.1080\/00397911.2016.1234622","volume":"46","author":"R Akhtar","year":"2016","unstructured":"Akhtar R, Yousaf M, Naqvi SAR, Irfan M, Zahoor AF, Hussain AI, et al. Synthesis of ciprofloxacin-based compounds: a review. Synth Commun. 2016;46:1849\u201379.","journal-title":"Synth Commun"},{"key":"373_CR36","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1093\/ajcp\/45.4_ts.493","volume":"45","author":"A Bauer","year":"1966","unstructured":"Bauer A. Antibiotic susceptibility testing by a standardized single disc method. Am J Clin Pathol. 1966;45:149\u201358.","journal-title":"Am J Clin Pathol"},{"key":"373_CR37","doi-asserted-by":"publisher","first-page":"42717","DOI":"10.1038\/srep42717","volume":"7","author":"A Daina","year":"2017","unstructured":"Daina A, Michielin O, Zoete V. SwissADME: a free web tool to evaluate pharmacokinetics, drug-likeness and medicinal chemistry friendliness of small molecules. Sci Rep. 2017;7:42717.","journal-title":"Sci Rep"},{"key":"373_CR38","doi-asserted-by":"publisher","first-page":"33","DOI":"10.1186\/1758-2946-3-33","volume":"1","author":"N O\u2019Boyle","year":"2011","unstructured":"O\u2019Boyle N, Banck M, James C, Morley C, Vandermeersch T, Hutchison G. Open babel: an open chemical toolbox. J Cheminformatics. 2011;1:33.","journal-title":"J Cheminformatics"},{"key":"373_CR39","doi-asserted-by":"publisher","first-page":"2785","DOI":"10.1002\/jcc.21256","volume":"30","author":"GM Morris","year":"2009","unstructured":"Morris GM, Huey R, Lindstrom W, Sanner MF, Belew RK, Goodsell DS, et al. AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility. J Comput Chem. 2009;30:2785\u201391.","journal-title":"J Comput Chem"},{"key":"373_CR40","doi-asserted-by":"publisher","first-page":"2257","DOI":"10.1016\/j.ejmech.2007.09.022","volume":"43","author":"SA Khan","year":"2008","unstructured":"Khan SA, Saleem K, Khan Z. Synthesis, structure elucidation and antibacterial evaluation of new steroidal-5-en-7-thiazoloquinoxaline derivatives. Eur J Med Chem. 2008;43:2257\u201361.","journal-title":"Eur J Med Chem"}],"container-title":["DARU Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-020-00373-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40199-020-00373-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40199-020-00373-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,10,8]],"date-time":"2021-10-08T12:15:59Z","timestamp":1633695359000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40199-020-00373-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,8]]},"references-count":40,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["373"],"URL":"https:\/\/doi.org\/10.1007\/s40199-020-00373-6","relation":{},"ISSN":["2008-2231"],"issn-type":[{"value":"2008-2231","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,8]]},"assertion":[{"value":"10 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2020","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}